Access the full text.
Sign up today, get DeepDyve free for 14 days.
This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables. Abstract On May 14, 1986, Congressman John Dingell, chairman of the US House Energy and Commerce Committee, along with ten cosponsors, introduced a bill, HR 4820, designed "to amend the Federal Food, Drug, and Cosmetic Act to ban the reimportation of drugs produced in the United States, to place restrictions on drug samples, to ban certain resales of drugs purchased by hospitals and other health care facilities, and for other purposes." Section 5 of this legislation would prohibit direct distribution of free samples of drugs to physicians by representatives or other employees of drug manufacturers. The manufacturer would be allowed to mail samples to physicians on written request, and the physician must return a receipt to the manufacturer. All records of such transactions must be retained by the manufacturer. On Sept 24, 1986, Senator Spark Matsunaga, with nine cosponsors, introduced identical legislation (S 2875) into the US Senate. These bills have
Archives of Dermatology – American Medical Association
Published: Jan 1, 1988
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.